Advanced-Stage Non–Small Cell Lung Cancer

Advances in Thoracic Oncology 2018

Jordi Remon, Myung Ju Ahn, Nicolas Girard, Melissa Johnson, Dong-Wan Kim, Gilberto Lopes, Rathi N. Pillai, Benjamin Solomon, Guillermo Villacampa, Qing Zhou

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of histologic subtype, with ICI use extended to include stage III disease, shifting the prognosis of all these patients. This new standard first-line approach opens a gap in standard second-line treatment, and older combinations may again become standard of care after progression during treatment with an ICI. The characterization of predictive biomarkers, patient selection, the definition of strategies with ICI combinations upon progression during treatment with ICIs, as well as prospective evaluation of the efficacy of ICIs in subpopulations (such as patients with poor performance status or brain metastases) represent upcoming challenges in advanced thoracic malignancies. In oncogene-addicted NSCLC three major steps were taken during 2018: next-generation tyrosine kinase inhibitors have overtaken more established agents as the new standard of care in EGFR and ALK receptor tyrosine kinase gene (ALK)-positive tumors. Mechanisms of acquired resistance have been reported among patients treated with next-generation EGFR tyrosine kinase inhibitors, reflecting the diversity of the landscape. One major step forward was the approval of personalized treatment in very uncommon genomic alterations, mainly fusions. This raises a new question about the challenge of implementation of next-generation sequencing in daily clinical practice to detect new and uncommon genomic alterations and to capture the heterogeneity of the mechanisms of acquired resistance during treatment, as well as the need to extend research into new therapeutic strategies to overcome them.

Original languageEnglish
Pages (from-to)1134-1155
Number of pages22
JournalJournal of Thoracic Oncology
Volume14
Issue number7
DOIs
StatePublished - Apr 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Thorax
Standard of Care
Protein-Tyrosine Kinases
Therapeutics
Oncogenes
Research
Patient Selection
Neoplasms
Biomarkers
Neoplasm Metastasis
Brain
Genes

Keywords

  • Advanced
  • Immune checkpoint inhibitors
  • Non–small cell lung cancer
  • Oncogenic drivers

Cite this

Remon, Jordi ; Ahn, Myung Ju ; Girard, Nicolas ; Johnson, Melissa ; Kim, Dong-Wan ; Lopes, Gilberto ; Pillai, Rathi N. ; Solomon, Benjamin ; Villacampa, Guillermo ; Zhou, Qing. / Advanced-Stage Non–Small Cell Lung Cancer : Advances in Thoracic Oncology 2018. In: Journal of Thoracic Oncology. 2019 ; Vol. 14, No. 7. pp. 1134-1155.
@article{f08dd9e7f02d4852b11eb77a1189b16a,
title = "Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018",
abstract = "In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of histologic subtype, with ICI use extended to include stage III disease, shifting the prognosis of all these patients. This new standard first-line approach opens a gap in standard second-line treatment, and older combinations may again become standard of care after progression during treatment with an ICI. The characterization of predictive biomarkers, patient selection, the definition of strategies with ICI combinations upon progression during treatment with ICIs, as well as prospective evaluation of the efficacy of ICIs in subpopulations (such as patients with poor performance status or brain metastases) represent upcoming challenges in advanced thoracic malignancies. In oncogene-addicted NSCLC three major steps were taken during 2018: next-generation tyrosine kinase inhibitors have overtaken more established agents as the new standard of care in EGFR and ALK receptor tyrosine kinase gene (ALK)-positive tumors. Mechanisms of acquired resistance have been reported among patients treated with next-generation EGFR tyrosine kinase inhibitors, reflecting the diversity of the landscape. One major step forward was the approval of personalized treatment in very uncommon genomic alterations, mainly fusions. This raises a new question about the challenge of implementation of next-generation sequencing in daily clinical practice to detect new and uncommon genomic alterations and to capture the heterogeneity of the mechanisms of acquired resistance during treatment, as well as the need to extend research into new therapeutic strategies to overcome them.",
keywords = "Advanced, Immune checkpoint inhibitors, Non–small cell lung cancer, Oncogenic drivers",
author = "Jordi Remon and Ahn, {Myung Ju} and Nicolas Girard and Melissa Johnson and Dong-Wan Kim and Gilberto Lopes and Pillai, {Rathi N.} and Benjamin Solomon and Guillermo Villacampa and Qing Zhou",
note = "Copyright {\circledC} 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.",
year = "2019",
month = "4",
doi = "10.1016/j.jtho.2019.03.022",
language = "English",
volume = "14",
pages = "1134--1155",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "7",

}

Remon, J, Ahn, MJ, Girard, N, Johnson, M, Kim, D-W, Lopes, G, Pillai, RN, Solomon, B, Villacampa, G & Zhou, Q 2019, 'Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018', Journal of Thoracic Oncology, vol. 14, no. 7, pp. 1134-1155. https://doi.org/10.1016/j.jtho.2019.03.022

Advanced-Stage Non–Small Cell Lung Cancer : Advances in Thoracic Oncology 2018. / Remon, Jordi; Ahn, Myung Ju; Girard, Nicolas; Johnson, Melissa; Kim, Dong-Wan; Lopes, Gilberto; Pillai, Rathi N.; Solomon, Benjamin; Villacampa, Guillermo; Zhou, Qing.

In: Journal of Thoracic Oncology, Vol. 14, No. 7, 04.2019, p. 1134-1155.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Advanced-Stage Non–Small Cell Lung Cancer

T2 - Advances in Thoracic Oncology 2018

AU - Remon, Jordi

AU - Ahn, Myung Ju

AU - Girard, Nicolas

AU - Johnson, Melissa

AU - Kim, Dong-Wan

AU - Lopes, Gilberto

AU - Pillai, Rathi N.

AU - Solomon, Benjamin

AU - Villacampa, Guillermo

AU - Zhou, Qing

N1 - Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

PY - 2019/4

Y1 - 2019/4

N2 - In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of histologic subtype, with ICI use extended to include stage III disease, shifting the prognosis of all these patients. This new standard first-line approach opens a gap in standard second-line treatment, and older combinations may again become standard of care after progression during treatment with an ICI. The characterization of predictive biomarkers, patient selection, the definition of strategies with ICI combinations upon progression during treatment with ICIs, as well as prospective evaluation of the efficacy of ICIs in subpopulations (such as patients with poor performance status or brain metastases) represent upcoming challenges in advanced thoracic malignancies. In oncogene-addicted NSCLC three major steps were taken during 2018: next-generation tyrosine kinase inhibitors have overtaken more established agents as the new standard of care in EGFR and ALK receptor tyrosine kinase gene (ALK)-positive tumors. Mechanisms of acquired resistance have been reported among patients treated with next-generation EGFR tyrosine kinase inhibitors, reflecting the diversity of the landscape. One major step forward was the approval of personalized treatment in very uncommon genomic alterations, mainly fusions. This raises a new question about the challenge of implementation of next-generation sequencing in daily clinical practice to detect new and uncommon genomic alterations and to capture the heterogeneity of the mechanisms of acquired resistance during treatment, as well as the need to extend research into new therapeutic strategies to overcome them.

AB - In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of histologic subtype, with ICI use extended to include stage III disease, shifting the prognosis of all these patients. This new standard first-line approach opens a gap in standard second-line treatment, and older combinations may again become standard of care after progression during treatment with an ICI. The characterization of predictive biomarkers, patient selection, the definition of strategies with ICI combinations upon progression during treatment with ICIs, as well as prospective evaluation of the efficacy of ICIs in subpopulations (such as patients with poor performance status or brain metastases) represent upcoming challenges in advanced thoracic malignancies. In oncogene-addicted NSCLC three major steps were taken during 2018: next-generation tyrosine kinase inhibitors have overtaken more established agents as the new standard of care in EGFR and ALK receptor tyrosine kinase gene (ALK)-positive tumors. Mechanisms of acquired resistance have been reported among patients treated with next-generation EGFR tyrosine kinase inhibitors, reflecting the diversity of the landscape. One major step forward was the approval of personalized treatment in very uncommon genomic alterations, mainly fusions. This raises a new question about the challenge of implementation of next-generation sequencing in daily clinical practice to detect new and uncommon genomic alterations and to capture the heterogeneity of the mechanisms of acquired resistance during treatment, as well as the need to extend research into new therapeutic strategies to overcome them.

KW - Advanced

KW - Immune checkpoint inhibitors

KW - Non–small cell lung cancer

KW - Oncogenic drivers

UR - http://www.scopus.com/inward/record.url?scp=85065977894&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2019.03.022

DO - 10.1016/j.jtho.2019.03.022

M3 - Review article

VL - 14

SP - 1134

EP - 1155

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 7

ER -